1. Home
  2. MNPR vs NPFD Comparison

MNPR vs NPFD Comparison

Compare MNPR & NPFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

N/A

Current Price

$55.74

Market Cap

372.9M

Sector

Health Care

ML Signal

N/A

Logo Nuveen Variable Rate Preferred & Income Fund

NPFD

Nuveen Variable Rate Preferred & Income Fund

N/A

Current Price

$19.17

Market Cap

474.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
MNPR
NPFD
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
372.9M
474.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MNPR
NPFD
Price
$55.74
$19.17
Analyst Decision
Strong Buy
Analyst Count
13
0
Target Price
$101.42
N/A
AVG Volume (30 Days)
150.5K
63.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.06
$16.79
52 Week High
$105.00
$20.12

Technical Indicators

Market Signals
Indicator
MNPR
NPFD
Relative Strength Index (RSI) 45.47 30.34
Support Level $56.15 $18.93
Resistance Level $61.30 $19.29
Average True Range (ATR) 3.32 0.20
MACD 0.75 -0.08
Stochastic Oscillator 53.45 13.64

Price Performance

Historical Comparison
MNPR
NPFD

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

About NPFD Nuveen Variable Rate Preferred & Income Fund

Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.

Share on Social Networks: